HOME > Investors > Press Releases
Subject Texas Heart Institute announces PAD phase II results on "Gene Therapy"
Writer ViroMed
Date 2016/01/21
On January 19th, Texas Heart Institute Stem Cell Center (THI) reports clinical trial phase II results of VM202-PAD on the January 2016 issue of Gene Therapy. The article reports VM202 can be a safe and effective therapeutic option to critical limb ischemia patients. (http://www.texasheart.org/AboutUs/News/2016-1-18news_VM202_promising_for_CLI.cfm)